Scholar Rock (SRRK)
(Delayed Data from NSDQ)
$10.33 USD
-0.34 (-3.19%)
Updated May 28, 2024 04:00 PM ET
After-Market: $10.31 -0.02 (-0.19%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Scholar Rock Holding Corporation [SRRK]
Reports for Purchase
Showing records 1 - 20 ( 118 total )
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Apitegromab?s SAPPHIRE Data in SMA (4Q24) Remains Key Focus, With Obesity Start in mid-2024; Reit Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Hitting the Gym with Apitegromab into the Clinic
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for SRRK 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Positive on Apitegromab?s Approval, and SRK-439?s Potential in Obesity; Reit. Buy and $30 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
The Scholar Polishing the SAPPHIRE in Preparation for the Big Reveal
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
Company: Scholar Rock Holding Corporation
Industry: Medical - Biomedical and Genetics
It?s a Great Time to be Experts in Myostatin Inhibition - Scholar Rock Looks to Target Obesity
Provider: H.C. Wainwright & Co., Inc.
Analyst: MALDONADO A